Business
Appointment of Joint Corporate Broker
Appointment of Joint Corporate Broker.
About this update from Renalytix Plc
[{"type":"text","content":"\n\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\n \nAppointment of Joint Corporate Broker\n \nLONDON and NEW YORK, 21 August 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the appointment of Oberon Capital (a trading name of Oberon Investments Limited) as Joint Corporate Broker with immediate effect.\n \n \nFor further information, please contact:\n \n\n\n\n\nRenalytix plc\n\n\nwww.renalytix.com\n\n\n\n\nJames McCullough, CEO\n\n\nVia Walbrook PR\n\n\n\n\n\n\n\n\n\n\n\n\nStifel (Nominated Adviser and Joint Broker)\n\n\nTel: 020 7710 7600\n\n\n\n\nNicholas Moore / Nick Harland / Ben Good\n\n\n \n\n\n\n\n\n\n\n \n\n\n\n\nOberon Capital (Joint Broker)\n\n\nTel: 020 3179 5300\n\n\n\n\nMike Seabrook / Nick Lovering\n \n\n\n \n\n\n\n\nInvestec Bank plc (Joint Broker)\n\n\nTel: 020 7597 4000\n\n\n\n\nGary Clarence / Shalin Bhamra\n\n\n \n\n\n\n\n\n\n\n \n\n\n\n\nWalbrook PR Limited\n\n\nTel: 020 7933 8780 or [email protected]\n\n\n\n\nAlice Woodings / Charlotte Edgar\n\n\nMob: 07407 804 654 / 07884 664 686\n\n\n\n\n\n\n\n\n\n\n\n\nCapComm Partners\n\n\n\n\n\n\n\nPeter DeNardo\n \n\n\nTel: 415-389-6400 or [email protected]\n\n\n\n\n \nAbout Renalytix\nRenalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.\n\n","length":8004,"tagName":"div"}]